AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00441740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
Study NCT00519532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h
Study NCT03703531 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiopulmonary resuscitation
Description: CPR performed because of out-of-hospital cardiac arrest
Study NCT00532259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Description: IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
Study NCT00555945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma3 intramedullary nail (Stryker)
Description: The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
Study NCT00555945 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screw
Description: The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
Study NCT02663570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Study NCT03701087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2800 IU daily till 26 weeks of pregnancy
Study NCT03701087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: 2800 IU daily till 26 weeks of pregnancy
Study NCT00884000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Study NCT00884000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zomacton
Study NCT01750281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib 75 mg
Description: Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
Study NCT01750281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m2
Description: Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
Study NCT01750281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2
Description: Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
Study NCT01750281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three placebo capsules will be administered orally uninterrupted twice daily.
Study NCT01142089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV MMX
Description: Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
Study NCT01490398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
Study NCT02915328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filterwire EZ™
Study NCT02915328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MO.MA Ultra
Study NCT02915328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Roadsaver®
Study NCT02915328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carotid Wallstent
Study NCT03175848 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy,radiotherapy
Description: Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
Study NCT04891601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: polypropelene mesh
Description: compare use mesh alone or combined mesh and darn repair
Study NCT00404443 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
Study NCT02904564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMP with 5-FU
Description: MMP with 5-FU using tattoo device
Study NCT02904564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MMP with Saline infusion
Description: MMP with saline infusion using tattoo device
Study NCT02200107 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self management education
Study NCT00467883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: high dosage
Study NCT01742923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex tailored intervention
Study NCT01742923 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Study NCT02001350 — intervention group
Intervention type: OTHER
Intervention: Ultrasonography
Study NCT03071432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Paced breathing at 6, 10 and 15 breaths per minute
Study NCT01652196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: 4 mg/kg as a 1-hour IV(intervenous) infusion
Study NCT01652196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2 IV infused over 2 hours
Study NCT03197818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5993 100/6/12.5 µg
Description: Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
Study NCT03197818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 160 µg budesonide + 4.5 µg formoterol fumarate
Description: Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
Study NCT03059979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
Study NCT01879579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Insulin Titration Intervention
Description: Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
Study NCT04175509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rectal acetaminophen
Description: Rectal 1300mg
Study NCT03059979 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride
Description: 100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
Study NCT03432182 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: electroencephalography
Description: Sleep states definition by electroencephalograpy
Study NCT02748707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm1
Description: Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Study NCT02748707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 2
Description: Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Study NCT02748707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 3
Description: Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
Study NCT02748707 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm 4
Description: Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
Study NCT00170547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
Study NCT00170547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
Study NCT00170547 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
Study NCT00830258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium 80 mg tablets
Description: 1 x 80 mg
Study NCT00830258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravachol® 80 mg tablets
Description: 1 x 80 mg
Study NCT06561906 — intervention group
Intervention type: OTHER
Intervention: Multimodal magnetic resonance imaging scanning, behavioral, genetic and plasma biomarker testing
Description: Multimodal magnetic resonance imaging scanning, including 3DT1, 3DT2, 3DFLAIR, functional MRI, DTI, NODDI, ASL, QSM behavioral testing, such as olfaction and spatial navigation genetic testing, such as APOE, BDNF plasma biomarker testing, such as ptau, Aβ42/40、NfL、GFAP
Study NCT02825160 — intervention group
Intervention type: DRUG
Intervention: Ventavis (Iloprost, BAYQ6256)
Description: The treatment of Ventavis should comply with the local product information
Study NCT00835146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 mg tablets
Description: 1 x 200 mg, single-dose fasting
Study NCT00835146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COPEGUS™
Description: 1 x 200 mg, single-dose fasting
Study NCT04145427 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a healthy combination protein, fat and vegetables daily will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management.
Study NCT04145427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LCD
Description: Initial Weight Loss consultation~1.5 hour session on how to do implement healthy diet and then have a 2-week follow-up class. Information on how to maintain a LCD will be provided provided.~4 lifestyle coaching sessions~Monthly visits for behavioral and dietary coaching as well as medication management.
Study NCT01714895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High insulin eu-hypoglycemic clamp
Description: Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
Study NCT01714895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low insulin eu-hypoglycemic clamp
Description: Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
Study NCT00031434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
Study NCT00031434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
Study NCT04515095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-only Fasting
Description: Participants consume only water for at least 7 days in an in-patient, residential setting with 24 hour medical supervision.
Study NCT03419403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid eye drops
Description: Solution, eye drop
Study NCT03419403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasoconstrictor eye drops
Description: Solution, eye drop
Study NCT03419403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold compress
Description: Cold compress
Study NCT03419403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ophthalmic steroid ointment
Description: Ointment
Study NCT03419403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Description: During the Chemoradiation Phase, participants were to receive depatuxizumab mafodotin at 2.0 mg/kg IV infusion over 30 - 40 minutes once every 2 weeks (Day 1 of Weeks 1, 3, and 5 of the 6-week regimen). During the Adjuvant Therapy Phase, participants were to receive depatuxizumab mafodotin at 1.25 mg/kg on Day 1 (± 2 days) and Day 15 (± 2 days) of each 28-day cycle as a 30 - 40 minute infusion for 12 cycles.
Study NCT03419403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide was to be administered according to the local standard of care. Duration of treatment was to be 6 - 12 cycles in the adjuvant phase and at the discretion of the investigator as supported by local standard of care.
Study NCT03419403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy treatment planning and administration was to be performed as per local institutional guidelines.
Study NCT04803487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robot-assisted cholecystectomy
Description: cholecystectomy was performed for patients using the Chinese Micro Hand S surgical robot.
Study NCT04803487 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: robot-assisted cholecystectomy
Description: cholecystectomy was performed for patients using the da Vinci surgical robot.
Study NCT02828449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapeutic education program
Study NCT01109966 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Special Medical Food
Description: Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.~Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age.
Study NCT01425086 — intervention group
Intervention type: DEVICE
Intervention: Embrace, PCM, warming blanket
Description: Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment.
Study NCT01380782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: 200 mg BID oral for 28 day cycle
Study NCT00935012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: Once daily 20 mg oral tafamidis (soft gelatin capsule)
Study NCT04737863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endodontic retreatment
Description: Root canal retreatment in cases with secondary root canal infection
Study NCT04737863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endodontic retreatment
Description: Root canal retreatment in cases with secondary root canal infection
Study NCT01885572 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TiLOOP Bra
Description: Titaniferously coated polypropylene mesh
Study NCT03867838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compliant support
Description: Participants will be given compliant arm support and their reachable workspace measured
Study NCT02300935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Study NCT02300935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Study NCT04175509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous acetaminophen
Description: Intravenous 1000mg
Study NCT00386971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine
Description: 3 grams daily in liquid form by mouth
Study NCT01652196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
Study NCT01652196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
Study NCT01421134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: 20, 40, 60 mg, flexible dose, once daily PM 6 weeks
Study NCT01421134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04311580 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intravesical electromotive administration of mitomycin
Study NCT01494974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FP7 Ahmed Glaucoma Drainage Implant
Description: Ahmed Glaucoma Valve model FP7
Study NCT01494974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FP8 Glaucoma Drainage Implant
Description: Ahmed Glaucoma Valve model FP8
Study NCT03494192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapula Retraction Exercise Group
Description: physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up.
Study NCT01652196 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Correlative Studies
Description: Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
Study NCT01652196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI
Description: Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
Study NCT03494192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapula Retraction +Glenohumeral Rotational Exercise Group
Description: physiotherapy program consists of manual therapy, supervised stretching and scapulothoracic and also rotator cuff muscles strengthening exercises and home exercise programme including stretching and strengthening exercises will be applied two times a week total 24 sessions.~After 24 sessions completed, patients will proceed to reduced exercise program until the 6-month follow-up
Study NCT02082093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine System